Hyperactivity News and Research

RSS

Exposure to common fire retardant may cause developmental malformations, behavioral changes and death

A new study by Baylor University environmental health researchers found that zebra fish exposed to several different technical mixtures of polybrominated diphenyl ethers (PBDEs) - a common fire retardant - during early development can cause developmental malformations, changes in behavior and death.

25 May 2011

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.

24 May 2011

Adjusting life goals can help family caregivers prevent depressive symptoms: Study

Caring for a family member with a mental illness can be a taxing experience marked by personal sacrifices and psychological problems.

21 May 2011

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

Despite recent concerns that medications for attention deficit hyperactivity disorder could increase the risk of cardiovascular events in children and adolescents, an observational study conducted by researchers at the University of Pennsylvania School of Medicine and HealthCore Inc. finds they are no more likely to die from a severe cardiovascular event than those who do not take the drugs.

16 May 2011

New autism research findings presented at 10th annual IMFAR

Much about autism is unknown, but researchers from the University of Rochester Medical Center (URMC) are working to learn more about the neurodevelopmental disorder and its most effective treatments. A team of researchers from URMC joins researchers from across the world in San Diego this week for the 10th annual International Meeting for Autism Research (IMFAR).

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Longer looks: Conservatives vs. liberals on Medicare - who's winning?

What you really need to know is that Tuesday was a great day in court for supporters of the Care Act and a very tough one for its opponents. That dynamic could easily change within the next six weeks or so when the 11th Circuit, the 6th Circuit, and the 3rd Circuit also hold their oral arguments on Care Act appeals. Either way, we are one step closer to the end of all of this, and you can bet that the justices were paying attention up the road a bit from Richmond.

13 May 2011

Breastfeeding leads to better behaviour in kids: Study

A new study shows that just four months of breastfeeding can cut the risk of children becoming badly behaved by almost a third. It found 16 per cent of children brought up on formula milk had problems including anxiety, lying, stealing and hyperactivity – more than double the proportion breastfed for at least four months.

10 May 2011

ADHD in children linked to stress and depression during pregnancy

According to the latest research women who are depressed or severely stressed during their pregnancy have a greater chance of having children with attention deficit hyperactivity disorder. It has been known till now that ADHD is largely inheritable but now it comes out that antenatal anxiety could contribute to 15 per cent of cases of the behavioural condition in children.

8 May 2011

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta extended-release 18, 27 and 36 mg tablets.

7 May 2011

Study explores impact of environmental toxins on health care costs and childhood morbidity

In three new studies published in the May issue of the journal Health Affairs, Mount Sinai School of Medicine researchers reveal the staggering economic impact of toxic chemicals and air pollutants in the environment, and propose new legislation to mandate testing of new chemicals and also those already on the market.

5 May 2011

Watson introduces generic version of Concerta

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., has launched an authorized generic version of Concerta as part of an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc.

2 May 2011

Brain function variations may increase person's risk of drug abuse

One can look at drug addiction as a moral issue, a social ill, or a criminal problem. But Lynn Oswald's experience studying the neuroscience of addiction tells her that it is something else entirely: a disease of the brain.

30 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

Unintentional overdose deaths in teens and adults have reached epidemic proportions in the U.S. In some 20 states in 2007 the number of unintentional drug poisoning deaths exceeded either motor vehicle crashes or suicides, two of the leading causes of injury death.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Mindfulness meditation may enhance mental abilities

The positive effects of mindfulness meditation on pain and working memory may result from an improved ability to regulate a crucial brain wave called the alpha rhythm.

22 Apr 2011

Parks and green environments impact social, psychological and physical health outcomes

Research shows that a walk in the park is more than just a nice way to spend an afternoon. It's an essential component for good health, according to University of Illinois environment and behavior researcher Frances "Ming" Kuo.

20 Apr 2011

Hyperactivity News and Research

Exposure to common fire retardant may cause developmental malformations, behavioral changes and death

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Adjusting life goals can help family caregivers prevent depressive symptoms: Study

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

New autism research findings presented at 10th annual IMFAR

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Longer looks: Conservatives vs. liberals on Medicare - who's winning?

Breastfeeding leads to better behaviour in kids: Study

ADHD in children linked to stress and depression during pregnancy

Alza files patent infringement suit against Impax in connection with Concerta

Study explores impact of environmental toxins on health care costs and childhood morbidity

Watson introduces generic version of Concerta

Brain function variations may increase person's risk of drug abuse

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Mindfulness meditation may enhance mental abilities

Parks and green environments impact social, psychological and physical health outcomes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News